Core Evidence.

Clinical impact summary for icatibant in acute attacks of hereditary angioedema type I and II

Outcome measure	Evidence	Implications
Disease-oriented evidence	Demonstrates efficacy for the treatment of acute hereditary angioedema attacks, including cutaneous, abdominal, and laryngeal attacks.19,29,31 No experience available in children.	Provides a complementary treatment to C1 inhibitor concentrate. According to international consensus patients may carry two doses of icatibant.14–18
Patient-oriented evidence
Self-administration	Patients are able to decide when to initiate a treatment, and they are able to safely self-administer icatibant earlier in their attacks.23	Potential to address a significant unmet need.
Quality of life	Not available.
Economic evidence	Variations in prices and availability of and access to icatibant among countries.54	Co-payments can represent important barriers to patients.55